Rx Propellant commits $100 million to build India's largest life sciences campus in Hyderabad
Rx Propellant, India’s leading science and R&D infrastructure platform established by Actis and part of General Atlantic, plans to invest $100 million to develop a large-format life sciences campus in Genome Valley, Hyderabad.
The development will deliver over one million square feet of advanced laboratory infrastructure in phases over the next six years. The first phase of the proposed campus will be completed by 2028.
Planned as a single, integrated campus with multiple blocks, the project is set to become the largest life sciences campus in Genome Valley. It is designed for Indian and global corporations seeking scalable, institutional-grade R&D infrastructure with resilient support systems, fully compliant buildings and high-performance electromechanical services.
Ashish Singh, CEO and Managing Director of Rx Propellant, said the investment reflects strong conviction in Hyderabad as a long-term anchor for life sciences R&D. “India’s life sciences sector is entering a phase of decisive scale-up, and buildings and infrastructure solutions must evolve in parallel to support this growth. This investment reflects our conviction in Genome Valley, Hyderabad as a long-term anchor for global and domestic R&D. Rx Propellant already has an established track record in Genome Valley, with its 1GV and 3GV campuses already 100% leased, hosting a mix of global and Indian life sciences companies,” said Singh.
Beyond Hyderabad, Rx Propellant is also developing the Navi Mumbai Research District, a 16-acre projec—as Mumbai’s largest integrated science and research ecosystem. Together, these developments signal the platform’s strategy to create institutional-quality science infrastructure across India’s key innovation clusters.
Brian Chinappi, Managing Director and Global Head of Real Estate & Data Centers at Actis, said that the high-quality physical infrastructure is foundational to building globally competitive life sciences ecosystems. “With increasing global interest in research, development and manufacturing partnerships within India, this investment underscores our conviction in India and in Hyderabad’s role as a leading R&D hub. Expanding Rx Propellant’s footprint in Genome Valley is a strategic step toward building a network of world-class life sciences campuses in India that can support companies at every stage of their growth journey from R&D to manufacturing,” he said.
Genome Valley has emerged over the last two decades as India’s most established life sciences hub, backed by a strong base of pharma and biotech firms, research institutions and skilled talent. Sustained public and private investment has shaped it into an integrated R&D ecosystem, with Rx Propellant’s upcoming campus set to further strengthen its appeal for global, innovation-led companies.
The company is focussed on shaping the next generation of research and manufacturing environments tailored to the needs of high-growth science companies. It has a development pipeline of around 4 million square feet, with all campuses aligned to global green building standards, including LEED and IFC EDGE certifications, to ensure long-term efficiency and lower environmental impact.
Actis is a leading investor in sustainable infrastructure across energy transition, digitalisation and supply chains. In October 2024, Actis combined with General Atlantic, forming a diversified platform with about $123 billion in assets under management, with Actis as its sustainable infrastructure arm.
The development will deliver over one million square feet of advanced laboratory infrastructure in phases over the next six years. The first phase of the proposed campus will be completed by 2028.
Planned as a single, integrated campus with multiple blocks, the project is set to become the largest life sciences campus in Genome Valley. It is designed for Indian and global corporations seeking scalable, institutional-grade R&D infrastructure with resilient support systems, fully compliant buildings and high-performance electromechanical services.
Ashish Singh, CEO and Managing Director of Rx Propellant, said the investment reflects strong conviction in Hyderabad as a long-term anchor for life sciences R&D. “India’s life sciences sector is entering a phase of decisive scale-up, and buildings and infrastructure solutions must evolve in parallel to support this growth. This investment reflects our conviction in Genome Valley, Hyderabad as a long-term anchor for global and domestic R&D. Rx Propellant already has an established track record in Genome Valley, with its 1GV and 3GV campuses already 100% leased, hosting a mix of global and Indian life sciences companies,” said Singh.
Beyond Hyderabad, Rx Propellant is also developing the Navi Mumbai Research District, a 16-acre projec—as Mumbai’s largest integrated science and research ecosystem. Together, these developments signal the platform’s strategy to create institutional-quality science infrastructure across India’s key innovation clusters.
Brian Chinappi, Managing Director and Global Head of Real Estate & Data Centers at Actis, said that the high-quality physical infrastructure is foundational to building globally competitive life sciences ecosystems. “With increasing global interest in research, development and manufacturing partnerships within India, this investment underscores our conviction in India and in Hyderabad’s role as a leading R&D hub. Expanding Rx Propellant’s footprint in Genome Valley is a strategic step toward building a network of world-class life sciences campuses in India that can support companies at every stage of their growth journey from R&D to manufacturing,” he said.
Genome Valley has emerged over the last two decades as India’s most established life sciences hub, backed by a strong base of pharma and biotech firms, research institutions and skilled talent. Sustained public and private investment has shaped it into an integrated R&D ecosystem, with Rx Propellant’s upcoming campus set to further strengthen its appeal for global, innovation-led companies.
The company is focussed on shaping the next generation of research and manufacturing environments tailored to the needs of high-growth science companies. It has a development pipeline of around 4 million square feet, with all campuses aligned to global green building standards, including LEED and IFC EDGE certifications, to ensure long-term efficiency and lower environmental impact.
Actis is a leading investor in sustainable infrastructure across energy transition, digitalisation and supply chains. In October 2024, Actis combined with General Atlantic, forming a diversified platform with about $123 billion in assets under management, with Actis as its sustainable infrastructure arm.
Next Story